Chikungunya vaccine

Chikungunya vaccine
Vaccine description
TargetChikungunya virus
Vaccine typeAttenuated
Clinical data
Trade namesIxchiq, others
AHFS/Drugs.comMonograph
License data
Routes of
administration		Intramuscular
ATC code
  • None
Legal status
Legal status

Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus.[7][9]

The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.[14]

The first chikungunya vaccine was approved for medical use in the United States in November 2023.[14] Chikungunya vaccines were also authorized in the European Union in May 2024.[10][12][15]

As of May 2025, the US Food and Drug Administration and Centers for Disease Control and Prevention recommended a pause in the use of the chikungunya vaccine (Ixchiq) in people aged 60 years of age and older based on reports of serious neurologic, cardiac, and other adverse events in vaccine recipients.[16] The European Medicines Agency paused the use of the vaccine in people aged 65 years of age and older in May 2025,[17] and resumed its use in July 2025.[18] The UK Medicines and Healthcare products Regulatory Agency paused the use of the vaccine in people aged 65 years of age and older in June 2025.[5]

  1. ^ "Register Of Innovative Drugs [Updated: 2024-07-04]". Health Canada. 4 July 2024. Retrieved 15 July 2024.
  2. ^ "Ixchiq Product information". Health Canada. 20 June 2024. Archived from the original on 15 July 2024. Retrieved 15 July 2024.
  3. ^ "Summary Basis of Decision for Ixchiq". Drug and Health Products Portal. 1 September 2012. Retrieved 17 December 2024.
  4. ^ "Regulatory Decision Summary for Ixchiq". Drug and Health Products Portal. 20 June 2024. Archived from the original on 7 December 2024. Retrieved 27 December 2024.
  5. ^ a b "iIxchiq Chikungunya vaccine: temporary suspension in people aged 65 years or older". GOV.UK. 18 June 2025. Archived from the original on 24 June 2025. Retrieved 28 July 2025.
  6. ^ "Ixchiq- chikungunya vaccine, live-attenuated injection, powder, lyophilized, for solution". DailyMed. 9 November 2023. Retrieved 2 April 2025.
  7. ^ a b "Ixchiq". U.S. Food and Drug Administration. 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023. This article incorporates text from this source, which is in the public domain.
  8. ^ "Vimkunya- chikungunya vaccine, recombinant injection, suspension". DailyMed. 18 February 2025. Retrieved 2 April 2025.
  9. ^ a b "Vimkunya". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 4 March 2025. Retrieved 3 March 2025.
  10. ^ a b "Ixchiq EPAR". European Medicines Agency (EMA). 30 May 2024. Archived from the original on 1 June 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  11. ^ Cite error: The named reference Ixchiq PI was invoked but never defined (see the help page).
  12. ^ a b "Vimkunya EPAR". European Medicines Agency (EMA). 30 January 2025. Archived from the original on 16 February 2025. Retrieved 16 February 2025. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  13. ^ Cite error: The named reference Vimkunya PI was invoked but never defined (see the help page).
  14. ^ a b "FDA Approves First Vaccine to Prevent Disease Caused by Chikungunya Virus". U.S. Food and Drug Administration (FDA) (Press release). 9 November 2023. Archived from the original on 9 November 2023. Retrieved 10 November 2023. This article incorporates text from this source, which is in the public domain.
  15. ^ "First vaccine to protect adults from Chikungunya". European Medicines Agency (EMA) (Press release). 31 May 2024. Retrieved 1 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  16. ^ "FDA and CDC Recommend Pause in Use of Ixchiq (Chikungunya Vaccine, Live) in Individuals 60 Years of Age and Older While Postmarketing Safety Reports are Investigated". U.S. Food and Drug Administration (FDA). 9 May 2025. Archived from the original on 10 June 2025. Retrieved 28 July 2025.
  17. ^ "EMA starts review of Ixchiq (live attenuated chikungunya vaccine)". European Medicines Agency (EMA) (Press release). 7 May 2025. Archived from the original on 9 July 2025. Retrieved 28 July 2025.
  18. ^ "Ixchiq: temporary restriction on vaccinating people 65 years and older to be lifted". European Medicines Agency (EMA) (Press release). 11 July 2025. Retrieved 27 July 2025.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.